Heterogeneity of breast cancer and implications of adjuvant chemotherapy

Breast Cancer

Volumn 15, Issue 1, 2008, Pages 31-34

  Razzak, A Rab ^a   Lin, Nancy U ^a   Winer, Eric P ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

Adjuvant therapy; Breast cancer subtypes; Heterogeneity

Indexed keywords

ANTINEOPLASTIC AGENT; ESTROGEN RECEPTOR;

ADJUVANT CHEMOTHERAPY; ARTICLE; BREAST TUMOR; DNA MICROARRAY; FEMALE; GENETICS; HUMAN; METABOLISM; PROTO ONCOGENE;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; FEMALE; GENES, ERBB-2; HUMANS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; RECEPTORS, ESTROGEN;

EID: 43149107209     PISSN: 13406868     EISSN: 18804233     Source Type: Journal    
DOI: 10.1007/s12282-007-0007-y     Document Type: Conference Paper

References (15)

1. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005;365(9472):1687-717.
2. Robert NJ, Eiermann W, Pienkowski T, Crown J, Martin M, Pawlicki M, Chan A, Bee V, Slamon D, Au H, on behalf of the BCIRG 006 Investigators. BCIRG 006: docetaxel and trastuzumab- based regimens improve DFS and OS over AC-T in node positive and high risk node negative HER2 positive early breast cancer patients: quality of life (QOL) at 36 months follow-up. J Clin Oncol 2007;25(2007 ASCO Annual Meeting Proceedings Part I):18S.
3. Albain K, Barlow W, O'Malley F, et al. Concurrent (CAFT) versus sequential (CAF-T) chemohormonal therapy (cyclophosphamide, doxorubicin, 5-fluorouracil, tamoxifen) versus T alone for postmenopausal, node-positive, estrogen (ER) and/or progesterone (PgR) receptor-positive breast cancer: mature outcomes and new biologic correlates on phase III intergroup trial 0100 (SWOG-8814). Proceedings of the 27th Annual Meeting of the San Antonio Breast Cancer Symposium 2004.
4. Pritchard K. Endocrinology and hormone therapy in breast cancer: endocrine therapy in premenopausal women. Breast Cancer Res. 2005;7(2):70-6.
5. Andre F, Broglio K, Roche H, Martin M, Penault-Lorca F, Hortobagyi GN, et al. Estrogen receptor expression and efficacy of docetaxel in early breast cancer: a pooled analysis of 3,490 patients included in two randomized trials. Proceedings of the 43rd Annual Meeting of the American Society of Clinical Oncology. 2007;25:537.
6. Sparano JA. TAILORx: trial assigning individualized options for treatment (Rx). Clin Breast Cancer. 2006;7(4):347-50. (Pubitemid 44717771)
7. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin. 2007;57(1):43-66. (Pubitemid 46148091)
8. Fan C, Oh DS, Wessels L, et al. Concordance among geneexpression-based predictors for breast cancer. N Engl J Med. 2006;355(6):560-9. (Pubitemid 44200649)
9. Berry DA, Cirrincione C, Henderson IC, et al. Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. JAMA. 2006;295(14):1658-67.
10. Mazouni C, Kau SW, Frye D, et al. Inclusion of taxanes, particularly weekly paclitaxel, in preoperative chemotherapy improves pathologic complete response rate in estrogen receptorpositive breast cancers. Ann Oncol. 2007;18(5):874-80. (Pubitemid 47054084)
11. Paik S, Tang G, Shak S, et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptorpositive breast cancer. J Clin Oncol. 2006;24(23):3726-34. (Pubitemid 46622311)
12. Sorlie T, Tibshirani R, Parker J, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA. 2003;100(14):8418-23. (Pubitemid 36842560)
13. Carey LA, Perou CM, Livasy CA, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA. 2006;295(21):2492-502. (Pubitemid 43854964)
14. Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005;353(16):1673-84. (Pubitemid 41464706)
15. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med. 2005;353(16):1659-72. (Pubitemid 41464705)